

**Vaccines for Children  
Oregon State-Supplied Vaccine  
Effective August 20, 2008**

Vaccines	Ages of Covered Children	All or High Risk?
DTaP	6 weeks through 6 years	All
Hepatitis A	1 year through 18 years	All
Hepatitis B	Birth through 18 years	All
Hib <sub>1</sub>	6 weeks through 59 months, certain 5-18 year olds	See footnote
HPV	9 years through 18 years, females	All
Influenza (2008-09 Season)	6 months through 18 years	All
IPV	6 weeks through 17 years	All
Meningococcal Vaccines (Both Polysaccharide and Conjugate), MPSV4 & MCV4 <sub>2</sub>	Ages 2 years through 18 years, as indicated	See footnotes
MMR	1 year through 18 years	All
MMR/V	1 year through 12 years (including 2 <sup>nd</sup> doses when indicated)	All
Pneumococcal Conjugate (PCV7)	6 weeks through 59 months	All
Pneumococcal Polysaccharide 23-valent (PPV23) <sub>3</sub>	2 through 18 years, high risk	See footnotes
Rotavirus	6 through 32 weeks	All
Td	7 through 18 years	All
Tdap <sup>4</sup>	10 through 18 years	See footnotes
Varicella	Two doses for all 1 year through 18 years	All

1) One dose of Hib vaccine is available for unimmunized high-risk children ages 5 through 18 years, with either functional or anatomical asplenia (SSD, post-splenectomy);

immunodeficiency; HIV infection; or immunosuppression due to HIV infection or chemotherapy.

- 2) MCV4 & MPSV4: **MCV4 is the preferred vaccine, whenever possible.** Routine vaccination of all persons aged 11--18 years with 1 dose of **MCV4** at the earliest opportunity. Persons aged 11--12 years should be routinely vaccinated at the 11--12 years health-care visit as recommended by ACIP. **MCV4** is also available for children ages 2 through 10 years at high risk, including: persons with terminal complement component deficiencies; persons with anatomic or functional asplenia; travelers to or residents of Sub-Saharan Africa's "Meningitis Belt," during December to June; visitors to Mecca in Saudi Arabia during annual Hajj; countries in which *N. Meningitidis* is hyperendemic or epidemic; also recommended for use in control of meningococcal outbreaks. MPSV4 is available as above when MCV4 is not available or contraindicated.
- 3) Pneumococcal Polysaccharide (23-valent) vaccine is available for high-risk children 2 years through 18 years who are:
  - a. Immunocompetent with chronic illness, including cardiovascular disease, pulmonary disease (e.g. COPD, emphysema, NOT asthma), diabetes, alcoholism, cirrhosis, cerebrospinal fluid leak, or cochlear implants;
  - b. Immunocompromised with increased risk of pneumococcal disease or its complications including those with bone or organ transplants, splenic dysfunction or absence, Hodgkin's disease, lymphoma, generalized malignancy, multiple myeloma, chronic renal failure, nephrotic syndrome;
  - c. Immunosuppressed from chemotherapy or high-dose corticosteroid therapy (14 days or longer);
  - d. HIV positive; and,
  - e. Residents of long-term care facilities.
  - f. Also consider vaccinating the following: persons living in special environments or social settings with an identified increased risk of pneumococcal disease or its complications, such as certain Native American (i.e. Alaskan Natives, Navajo and Apache) populations.
- 4) Boostrix® is licensed for ages **10** through 18 years of age; Adacel® is licensed for ages **11** through 64.

If you have any questions about this chart or the footnotes, or would like the document in an alternate format (e.g. Braille), please call the Public Health Division Immunization Program at (971) 673-0300.